WEKO3
アイテム
Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in Exudative Age-Related Macular Degeneration: 52- and 96-Week Findings from ALTAIR : A Randomized Controlled Trial.
http://hdl.handle.net/10422/00012632
http://hdl.handle.net/10422/00012632da61af83-003a-4fa5-8fa2-ef19f5780047
名前 / ファイル | ライセンス | アクション |
---|---|---|
s12325-020-01236-x (731.7 kB)
|
This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third-party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
|
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2020-03-06 | |||||
タイトル | ||||||
タイトル | Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in Exudative Age-Related Macular Degeneration: 52- and 96-Week Findings from ALTAIR : A Randomized Controlled Trial. | |||||
言語 | ||||||
言語 | eng | |||||
キーワード | ||||||
言語 | en | |||||
主題Scheme | Other | |||||
主題 | Aflibercept | |||||
キーワード | ||||||
言語 | en | |||||
主題Scheme | Other | |||||
主題 | Anti-vascular endothelial growth factor agents | |||||
キーワード | ||||||
言語 | en | |||||
主題Scheme | Other | |||||
主題 | Exudative age-related macular degeneration | |||||
キーワード | ||||||
言語 | en | |||||
主題Scheme | Other | |||||
主題 | Ophthalmology | |||||
キーワード | ||||||
言語 | en | |||||
主題Scheme | Other | |||||
主題 | Treat-and-extend | |||||
キーワード | ||||||
言語 | en | |||||
主題Scheme | Other | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
著者 |
OHJI, Masahito
× OHJI, Masahito× TAKAHASHI, Kanji× OKADA, Annabelle Ayame× Kobayashi, Masato× MATSUDA, Yoshimi× TERANO, Yasuhiro× HANEMOTO, Tsukasa× KAGA, Tatsushi× KOUNO, Takeya× KITAMEI, Hirokuni× SATO, Shinpei× YANAI, Ryoji× Uchio, Eiichi× MIYATA, Kazunori× 若林, 賢彦× MAENO, Takatoshi× YASUKAWA, Tsutomu× HORIGUCHI, Masayuki× NISHIMURA, Tetsuya× KAWAHARA, Akiteru× KURIMOTO, Yasuo× MURAI, Kenichi× KOBAYASHI, Namie× KIMURA, Wataru× MATSUSHITA, Eriko× SONODA, Kohei× ALTAIR Investigators |
|||||
著者別名 |
大路, 正人
× 大路, 正人 |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | PURPOSE: To evaluate efficacy and safety of intravitreal injections of aflibercept (IVT-AFL) treat-and-extend (T&E) dosing regimens in treatment-naïve patients with exudative age-related macular degeneration (AMD). |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | METHODS: Adults aged at least 50 years old with exudative AMD and best-corrected visual acuity (BCVA) of 73-25 Early Treatment Diabetic Retinopathy Study (ETDRS) letters were included. Patients received three monthly doses of IVT-AFL 2 mg. At week 16, patients were randomized 1:1 to IVT-AFL T&E with either 2- or 4-week adjustments. The primary endpoint was mean change in BCVA from baseline to week 52. Outcomes were assessed at weeks 52 and 96. |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | RESULTS: Baseline characteristics were comparable between the groups (n = 123 each). Over 52 weeks, mean number of injections was 7.2 and 6.9 and mean last injection interval was 10.7 and 11.8 weeks, for the 2- and 4-week groups, respectively. From baseline, mean change in BCVA was + 9.0 and + 8.4 letters (week 52) and + 7.6 and + 6.1 letters (week 96); mean change in central retinal thickness was - 134.4 µm and - 126.1 µm (week 52) and - 130.5 µm and - 125.3 µm (week 96). Last injection interval before week 52 was at least 12 weeks in 42.3% and 49.6% of patients and 56.9% and 60.2% before week 96. Over 96 weeks, mean number of injections was 10.4 (both groups). The safety profile of IVT-AFL was consistent with previous reports. |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | CONCLUSIONS: IVT-AFL administered using two different T&E regimens for treatment-naïve exudative AMD improved functional and anatomic outcomes at week 52 and outcomes were maintained to week 96. Outcomes were similar between the 2- and 4-week groups. |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | TRIAL REGISTRATION: ClinicalTrials.gov identifier, NCT02305238. |
|||||
書誌情報 |
en : Advances in therapy 巻 37, 号 3, p. 1173-1187, 発行日 2020-03 |
|||||
出版者 | ||||||
出版者 | Springer Nature | |||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 1865-8652 | |||||
PMID | ||||||
関連タイプ | isIdenticalTo | |||||
識別子タイプ | PMID | |||||
関連識別子 | 32016788 | |||||
DOI | ||||||
関連タイプ | isIdenticalTo | |||||
識別子タイプ | DOI | |||||
関連識別子 | https://doi.org/10.1007/s12325-020-01236-x | |||||
関連名称 | 10.1007/s12325-020-01236-x | |||||
権利 | ||||||
権利情報 | © The Author(s) 2020 | |||||
著者版フラグ | ||||||
出版タイプ | VoR | |||||
出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||
資源タイプ | ||||||
内容記述タイプ | Other | |||||
内容記述 | Journal Article |